Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment pro…
Biotechnology
DK, Bagsvaerd [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Novo Nordisk A/S's gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E | E | E | E | E | E | |||||||
2015 | - | 6.627 | - | 107,255 | - | 29,785 | - | 51,002 | - | 46,940 | - | 30,620 |
2016 | 13.5600 | 7.766 | 107,927 | 115,075 | 34,860 | 263,811 | 52,488 | 54,721 | 49,444 | 50,362 | 32,169 | 32,852 |
2017 | 7.5000 | 7.923 | 111,780 | 114,363 | 37,925 | 235,536 | 51,616 | 54,383 | 48,432 | 50,051 | 32,339 | 32,649 |
2018 | 7.7100 | 8.050 | 111,696 | 111,597 | 38,130 | 239,563 | 52,164 | 53,067 | 48,967 | 48,840 | 32,124 | 31,859 |
2019 | 7.9800 | 8.045 | 111,831 | 118,180 | 38,628 | 249,843 | 51,164 | 56,198 | 47,248 | 51,721 | 33,313 | 33,739 |
2020 | 8.2000 | 8.837 | 122,021 | 125,101 | 38,951 | 252,296 | 57,791 | 59,489 | 52,483 | 54,750 | 35,830 | 35,714 |
2021 | 9.0300 | 10.304 | 126,946 | 139,787 | 42,138 | 292,366 | 60,215 | 66,472 | 54,126 | 61,178 | 36,886 | 39,907 |
2022 | 10.4000 | 12.162 | 140,800 | 175,684 | 47,757 | 343,865 | 67,556 | 83,543 | 58,644 | 76,888 | 41,058 | 50,156 |
2023 | 12.2600 | 18.111 | 176,954 | 226,803 | 55,525 | 370,752 | 82,040 | 107,851 | 74,809 | 99,261 | 50,684 | 64,749 |
2024 | 18.6700 | 22.752 | 232,261 | 286,513 | 83,683 | 102,266 | 112,940 | 136,245 | 102,574 | 125,393 | 61,598 | 81,796 |
2025 | - | 28.518 | - | 345,067 | - | 128,183 | - | 164,089 | - | 151,019 | - | 98,512 |
2026 | - | 34.393 | - | 403,696 | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
2027 | - | 38.437 | - | 443,284 | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
2028 | - | 43.307 | - | 501,163 | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
Overweight
Prev. Grade
n/a
Nov. 6, 2024
Overweight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
Underweight
Prev. Grade
Underweight
Nov. 6, 2024
Underweight
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-68.012% $57.81 · MISS
Nov. 6, 2024Price Then
$110.13
Price Target
$142.81
Price Now
$85.00